Drug intelligence / Profile preview

SNTX-AXN

Development stage: Preclinical
Lead developer: Sensorium Therapeutics
Modality: Small Molecules

Overview

SNTX-AXN is a preclinical, small-molecule, fast-acting anxiolytic discovered and developed by Sensorium Therapeutics using its AI- and biology-driven Biodynamic Discovery Platform to generate first-in-class central nervous system (CNS) drugs inspired by natural compounds with prior human use.[3][5][9][12] The agent is being advanced for anxiety disorders, with additional preclinical work indicating potential utility in depressive disorders, but detailed target, receptor profile, and molecular mechanism of action have not yet been publicly disclosed.[3][5][9][12]

Beyond the preview

Go deeper on SNTX-AXN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNTX-AXN.

Explore the full profile